Fibrobiologics posted a GAAP net loss of USD 4.12 million in Q2 2026, narrowing from a GAAP net loss of USD 4.66 million.
Operating loss narrowed to USD 4.03 million as total operating expenses fell to USD 4.03 million from USD 4.49 million.
R&D expenses declined to USD 1.66 million from USD 2.04 million, while general and administrative costs edged down to USD 2.38 million from USD 2.45 million.
Cash position and clinical update
Cash and cash equivalents totaled USD 3.5 million at June 30, 2026; net cash used in operating activities improved to USD 7.66 million from USD 9.26 million.
CYWC628 diabetic foot ulcer trial enrollment lagged; interim six-week data expected in the second half of 2026, with Nasdaq delisting proceedings stayed pending appeal.
FBLG•
